AtriCure, Inc. ATRC
54.90 USD -0.12 (-0.22%)
As ofNov 18, 2026, 2:54 PM EST
54.09 Day range 56.47
25.36 52-week range 66.02
- YTD
- +38.78%
- 1 year
- +65.56%
News
benzinga.com Freedom Capital Markets Maintains Hold on AtriCure, Maintains $57 Price Target Freedom Capital Markets analyst Keith Hinton maintains AtriCure (NASDAQ:ATRC) with a Hold and maintains $57 price target.
businesswire.com AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and…benzinga.com Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $67 Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $67.
benzinga.com Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70 Piper Sandler analyst Matt O'Brien reiterates AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $60 to $70.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results AtriCure beat Q3 estimates, raised FY2026 EPS and sales guidance, and saw analysts lift price targets to $70; shares fell 2%.benzinga.com Needham Maintains Buy on AtriCure, Raises Price Target to $70 Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $64 to $70.
benzinga.com BTIG Maintains Buy on AtriCure, Raises Price Target to $70 BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.
benzinga.com AtriCure Q3 2026 Earnings Call Transcript AtriCure (NASDAQ:ATRC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com AtriCure Q3 Adj. EPS $0.17 Beats $(0.05) Estimate, Sales $154.450M Beat $151.217M Estimate AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.05) by 440 percent. This is a 1800 percent increase over losses of $(0.01) per…
benzinga.com AtriCure Raises FY2026 Adj EPS Guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 Est; Raises FY2026 Sales Guidance from $602.000M-$610.000M to $606.000M-$610.000M vs $606.219M Est AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.24-$0.32 to $0.40-$0.46 vs $0.15 analyst estimate. Raises FY2026 sales outlook from $602.000 million-$610.000 million to $606.000…
benzinga.com Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68 Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
